Unlearn Raises $50 Million Series C to Optimize Clinical Research With AI-Powered Digital Twin Technology
Healthcare IT Today
FEBRUARY 29, 2024
Understanding this, Unlearn has partnered with regulatory experts since its founding and now has a qualification from the European Medicines Agency for use as the primary analysis in phase 2 and 3 clinical trials with continuous outcomes as well as agreement from the U.S.
Let's personalize your content